Literature DB >> 18799288

Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study.

Donald C Goff1, Corinne Cather, Jennifer D Gottlieb, A Eden Evins, Jared Walsh, Lisa Raeke, Michael W Otto, David Schoenfeld, Michael F Green.   

Abstract

BACKGROUND: Daily dosing with d-cycloserine has inconsistently improved negative symptoms in schizophrenia patients, whereas intermittent dosing significantly facilitated exposure-based therapy in two studies of patients with phobic anxiety. In animal models, single-dose administration enhances memory consolidation, but tachyphylaxis develops with repeated dosing. The objective of this exploratory study was to assess whether once-weekly dosing with d-cycloserine will produce persistent improvements in negative symptoms and cognition.
METHODS: Fifty stable adult schizophrenia outpatients treated with any antipsychotic except clozapine were enrolled and 38 were randomized, double-blind, in a parallel-group, eight-week add-on trial of d-cycloserine 50 mg or placebo administered once-weekly. Symptom rating scales and a cognitive battery were administered at baseline and week 8 before the dose of study drug. As an exploratory analysis of memory consolidation, the Logical Memory Test, modified to measure recall after 7 days, was administered at baseline and after the first weekly dose of d-cycloserine. The primary outcome measures were change from baseline to week 8 on the SANS total score and on a composite cognitive score.
RESULTS: Thirty-three subjects (87%) completed the trial. d-cycloserine significantly improved SANS total scores compared to placebo at week 8. Cognitive performance did not improve with d-cycloserine at 8 weeks. Delayed thematic recall on the Logical Memory Test was significantly improved with the first dose of d-cycloserine compared to placebo. Performance on immediate thematic recall and item recall on the Logical Memory Test did not differ between treatments.
CONCLUSIONS: Once-weekly dosing with d-cycloserine for 8 weeks produced persistent improvement of negative symptoms compared to placebo, although statistical significance was, in part, the result of worsening of negative symptoms with placebo. Consistent with animal models, a single dose of d-cycloserine facilitated memory consolidation tested after 7 days on a test of thematic recall. These results must be considered preliminary since a number of outcomes were examined without correction for multiple tests. These findings suggest that once-weekly dosing with d-cycloserine for the treatment of negative symptoms merits further study, as do d-cycloserine effects on memory consolidation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18799288      PMCID: PMC2628436          DOI: 10.1016/j.schres.2008.08.012

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  36 in total

1.  A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia.

Authors:  D C Goff; G Tsai; J Levitt; E Amico; D Manoach; D A Schoenfeld; D L Hayden; R McCarley; J T Coyle
Journal:  Arch Gen Psychiatry       Date:  1999-01

2.  Behavioral and neuroendocrine effects of the partial NMDA agonist D-cycloserine in healthy subjects.

Authors:  B N van Berckel; C Lipsch; S Timp; C Gispen-de Wied; H Wynne; J M van Ree; R S Kahn
Journal:  Neuropsychopharmacology       Date:  1997-05       Impact factor: 7.853

3.  SAFTEE: a technique for the systematic assessment of side effects in clinical trials.

Authors:  J Levine; N R Schooler
Journal:  Psychopharmacol Bull       Date:  1986

4.  The positive and negative syndrome scale (PANSS) for schizophrenia.

Authors:  S R Kay; A Fiszbein; L A Opler
Journal:  Schizophr Bull       Date:  1987       Impact factor: 9.306

5.  D-cycloserine, a partial agonist at the glycine site coupled to N-methyl-D-aspartate receptors, improves visual recognition memory in rhesus monkeys.

Authors:  N Matsuoka; T G Aigner
Journal:  J Pharmacol Exp Ther       Date:  1996-08       Impact factor: 4.030

6.  Desensitization of the NMDA receptor complex by glycinergic ligands in cerebellar granule cell cultures.

Authors:  K M Boje; G Wong; P Skolnick
Journal:  Brain Res       Date:  1993-02-19       Impact factor: 3.252

7.  Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention.

Authors:  D Quartermain; J Mower; M F Rafferty; R L Herting; T H Lanthorn
Journal:  Eur J Pharmacol       Date:  1994-05-12       Impact factor: 4.432

8.  D-serine added to antipsychotics for the treatment of schizophrenia.

Authors:  G Tsai; P Yang; L C Chung; N Lange; J T Coyle
Journal:  Biol Psychiatry       Date:  1998-12-01       Impact factor: 13.382

9.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.

Authors:  J H Krystal; L P Karper; J P Seibyl; G K Freeman; R Delaney; J D Bremner; G R Heninger; M B Bowers; D S Charney
Journal:  Arch Gen Psychiatry       Date:  1994-03

10.  Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia.

Authors:  D C Goff; G Tsai; D S Manoach; J T Coyle
Journal:  Am J Psychiatry       Date:  1995-08       Impact factor: 18.112

View more
  52 in total

1.  Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia.

Authors:  Surendra P Singh; Vidhi Singh
Journal:  CNS Drugs       Date:  2011-10-01       Impact factor: 5.749

Review 2.  Glutamate receptor ion channels: structure, regulation, and function.

Authors:  Stephen F Traynelis; Lonnie P Wollmuth; Chris J McBain; Frank S Menniti; Katie M Vance; Kevin K Ogden; Kasper B Hansen; Hongjie Yuan; Scott J Myers; Ray Dingledine
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

Review 3.  The treatment of cognitive impairment in schizophrenia.

Authors:  Donald C Goff; Michele Hill; Deanna Barch
Journal:  Pharmacol Biochem Behav       Date:  2010-11-27       Impact factor: 3.533

4.  Room to move: Plasticity in early auditory information processing and auditory learning in schizophrenia revealed by acute pharmacological challenge.

Authors:  Neal R Swerdlow; Savita G Bhakta; Gregory A Light
Journal:  Schizophr Res       Date:  2018-04-05       Impact factor: 4.939

Review 5.  Auditory System Target Engagement During Plasticity-Based Interventions in Schizophrenia: A Focus on Modulation of N-Methyl-D-Aspartate-Type Glutamate Receptor Function.

Authors:  Joshua T Kantrowitz; Neal R Swerdlow; Walter Dunn; Sophia Vinogradov
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2018-02-22

6.  D-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia.

Authors:  Jennifer D Gottlieb; Corinne Cather; Meghan Shanahan; Timothy Creedon; Eric A Macklin; Donald C Goff
Journal:  Schizophr Res       Date:  2011-06-30       Impact factor: 4.939

Review 7.  D-cycloserine: an evolving role in learning and neuroplasticity in schizophrenia.

Authors:  Donald C Goff
Journal:  Schizophr Bull       Date:  2012-02-23       Impact factor: 9.306

Review 8.  The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia.

Authors:  Samuel M Cohen; Richard W Tsien; Donald C Goff; Michael M Halassa
Journal:  Schizophr Res       Date:  2015-01-09       Impact factor: 4.939

Review 9.  Towards medication-enhancement of cognitive interventions in schizophrenia.

Authors:  Hsun-Hua Chou; Elizabeth Twamley; Neal R Swerdlow
Journal:  Handb Exp Pharmacol       Date:  2012

Review 10.  Dendritic structural plasticity and neuropsychiatric disease.

Authors:  Marc P Forrest; Euan Parnell; Peter Penzes
Journal:  Nat Rev Neurosci       Date:  2018-03-16       Impact factor: 34.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.